SOUTH PLAINFIELD, NJ--(Marketwired - Dec 14, 2016) - Following Majesco Entertainment, Inc.'s (NASDAQ: COOL) ("Majesco") announcement on 12/8/16 that it had signed a definitive merger agreement with PolarityTE, Inc. ("Polarity"), Polarity has revealed the first wave of their World Class Clinical Advisory Board, as Drs. Michael Grant, Stephen Milner, and Anand Kumar. Chairman and CEO, Denver Lough MD, PhD elaborated, "Our goal is to build an entirely new type of regenerative medicine company with PolarityTE™. The PolarityTE™ Clinical Advisory Board will play a critical role in translating our regenerative technology into pragmatic clinical practice, helping us address the realities of the field on a real-time basis. It is this tangible feedback that allows PolarityTE™ technology to evolve quickly under the guidance of thought leaders in reconstructive surgery and regenerative medicine, while permitting our platform to break into new markets and develop new integrative technologies. We are extremely excited to announce the first tier of our world class clinical advisory board" as:

Michael P Grant MD, PhD, FACS
Paul N. Manson Distinguished Professor and Chief
Plastic, Reconstructive and Maxillofacial Surgery
R Adams Cowley Shock Trauma Center
University of Maryland Medical Center

Stephen Milner MD, DDS, DSc, FRCSE, FACS
Professor of Plastic and Reconstructive Surgery and Pediatrics at Johns Hopkins School of Medicine,
Director of the Johns Hopkins Burn Center,
Professor at the Bloomberg School of Public Health,
Director of the Michael D Hendrix Burn Research Center,
Adjunct Professor Uniformed Services University of the Health Sciences,
Honorary Civilian Consultant Advisor to the British Army in Plastic Surgery and Burns

Anand Kumar MD, FACS
Associate Professor of Plastic and Reconstructive Surgery
Director, Center for Pediatric Craniofacial Surgery
Johns Hopkins School of Medicine

About PolarityTE
PolarityTE, Inc. is the owner of a novel regenerative medicine and tissue engineering platform developed and patented by Denver Lough MD, PhD. This radical and proprietary technology employs a patients' own cells for the healing of full-thickness functionally-polarized tissues. If clinically successful, the PolarityTE platform will be able to provide medical professionals with a truly new paradigm in wound healing and reconstructive surgery by utilizing a patient's own tissue substrates for the regeneration of skin, bone, muscle, cartilage, fat, blood vessels and nerves. It is because PolarityTE uses a natural and biologically sound platform technology, which is readily adaptable to a wide spectrum of organ and tissue systems, that the company and its world-renowned clinical advisory board, are poised to drastically change the field and future of translational regenerative medicine. More info can be found online at Welcome to the Shift™

Forward Looking Statements
Certain statements contained in this release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward looking statements contained in this release relate to, among other things, the Company's ongoing compliance with the requirements of The NASDAQ Stock Market and the Company's ability to maintain the closing bid price requirements of The NASDAQ Stock Market on a post reverse split basis. They are generally identified by words such as "believes," "may," "expects," "anticipates," "should'" and similar expressions. Readers should not place undue reliance on such forward-looking statements, which are based upon the Company's beliefs and assumptions as of the date of this release. The Company's actual results could differ materially due to risk factors and other items described in more detail in the "Risk Factors" section of the Company's Annual Reports filed with the SEC (copies of which may be obtained at Subsequent events and developments may cause these forward-looking statements to change. The Company specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.